VKTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Viking Therapeutics Inc (VKTX) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company has positive developments in its pipeline, such as VK2735 entering phase 3 trials, the pre-market price is down 2.20%, insiders are selling heavily, and financial performance remains weak with significant net losses. The lack of strong trading signals and mixed technical indicators suggest waiting for a better entry point or more clarity on the company's financial and market performance.
The MACD is positive but contracting, RSI is neutral at 61.757, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 32.044, with resistance at 34.71 and support at 29.378. Pre-market price is down 2.20%, suggesting bearish sentiment.
VK2735 entering phase 3 clinical trials with strong mid-stage data positions Viking Therapeutics well in the competitive weight-loss drug market. The company's focus on obesity drug development aligns with a growing market trend.
Insiders are selling heavily, with a 206.50% increase in selling over the last month. The company has no revenue and continues to report significant net losses (-$157.66M in Q4 2025). The pre-market price is down 2.20%, and hedge funds remain neutral.
In Q4 2025, Viking Therapeutics reported no revenue growth (0% YoY) and a net loss of -$157.66M, which is an improvement of 345.16% YoY. EPS improved to -1.38, up 331.25% YoY, but the company remains unprofitable.
Morgan Stanley analyst Michael Ulz recently lowered the price target from $102 to $99 while maintaining an Overweight rating, reflecting cautious optimism about the stock's long-term potential.
